Understanding the emergence and evolution of new business models in the UK regenerative medicine sector
Understanding the emergence and evolution of new business models in the UK regenerative medicine sector
复制标题
DOI：
10.1080/09537325.2019.1685087
复制
发表时间：
2019-11
影响因子：
3.4
通讯作者：
Geoffrey Banda;James Mittra;J. Tait;Andrew Watkins;O. Omidvar
中科院分区：
文献类型：
--
作者：
Geoffrey Banda;James Mittra;J. Tait;Andrew Watkins;O. Omidvar
本文基于10个案例，对英国六种不断发展的再生商业（RM）模式进行了识别、表征和分析。我们的概念框架从当代商业模式和价值链文献中提取了四个关键要素；架构/结构，价值创造和提取，网络和联系，以及治理。使用案例研究方法，我们确定了以下商业模式：材料和服务提供；提前退出：第I/II阶段；制造和扩大规模；转化服务;虚拟的;和集成。所有的商业模式仍然是收入前模式，除了生产和扩大规模，后者通过合同生产临床试验的疗法产生收入。RM行业仍在不断发展，因此业务模式仍在不断变化。该行业面临的两个关键挑战是可扩展性和可持续性，这为先发制人的政策和实践干预带来了挑战。我们的结论是，先发制人的政策设计应该支持价值链升级，特别关注RM创新生态系统的短期、中期和长期可持续性，特别是在公共资金撤出时能够接管的广泛中小企业基础的演变。即使在价值链升级发生时，适当和适应性的监管环境对于支持不断发展的商业模式也至关重要。
ABSTRACT This paper identifies, characterises and analyses six evolving regenerative business (RM) models in the UK based on 10 cases we studied. Our conceptual framework extracts four key elements from contemporary business model and value chain literature; architecture/structure, value creation and extraction, networks and linkages, and governance. Using the case study method, we identified the following business models: materials and service provision; early exit: Phase I/II; manufacturing and scale up; translational services; virtual; and integrated. All the business models are still pre-revenue, except for manufacturing and scale up which generates revenue from contract manufacturing therapies for clinical trials. The RM sector is still evolving and consequently the business models are still in flux. Two key challenges for the sector are scalability and sustainability, which creates challenges for pre-emptive policy and practice interventions. We conclude that pre-emptive policy design should support value chain upgrading, paying particular attention to short, medium and long-term sustainability of the RM innovation eco-system, especially evolution of a broad base of SMEs that can take over when public funding is withdrawn. A proportionate and adaptive regulatory environment will be critical to supporting evolving business models even as value chain upgrading occurs.